Chimerism and post-HCT autoimmune disease
| Chimerism . | No de novo autoimmunity at day 100 or later . | De novo autoimmunity at day 100 or later . | P . |
|---|---|---|---|
| At day 100 | |||
| All chimerism (n = 112)* | .5841 | ||
| Full | 58 (88) | 8 (12) | |
| Mixed | 38 (83) | 8 (17) | |
| T-cell chimerism (n = 84) | .2721 | ||
| Full | 53 (91) | 5 (9) | |
| Mixed | 21 (81) | 5 (19) | |
| B-cell chimerism (n = 59) | .1299 | ||
| Full | 44 (88) | 6 (12) | |
| Mixed | 6 (67) | 3 (33) | |
| Myeloid chimerism (n = 83) | .6802 | ||
| Full | 57 (90) | 6 (10) | |
| Mixed | 17 (85) | 3 (15) |
| Chimerism . | No de novo autoimmunity at day 100 or later . | De novo autoimmunity at day 100 or later . | P . |
|---|---|---|---|
| At day 100 | |||
| All chimerism (n = 112)* | .5841 | ||
| Full | 58 (88) | 8 (12) | |
| Mixed | 38 (83) | 8 (17) | |
| T-cell chimerism (n = 84) | .2721 | ||
| Full | 53 (91) | 5 (9) | |
| Mixed | 21 (81) | 5 (19) | |
| B-cell chimerism (n = 59) | .1299 | ||
| Full | 44 (88) | 6 (12) | |
| Mixed | 6 (67) | 3 (33) | |
| Myeloid chimerism (n = 83) | .6802 | ||
| Full | 57 (90) | 6 (10) | |
| Mixed | 17 (85) | 3 (15) |
| Chimerism . | No de novo autoimmunity at 6 mo or later . | De novo autoimmunity at 6 mo or later . | P . |
|---|---|---|---|
| At 6 mo | |||
| All chimerism (n = 82)* | .3938 | ||
| Full | 45 (96) | 2 (4) | |
| Mixed | 31 (89) | 4 (11) | |
| T-cell chimerism (n = 65) | .5995 | ||
| Full | 45 (94) | 3 (6) | |
| Mixed | 15 (88) | 2 (12) | |
| B-cell chimerism (n = 48) | .2865 | ||
| Full | 41 (95) | 2 (5) | |
| Mixed | 4 (80) | 1 (20) | |
| Myeloid chimerism (n = 62) | .0494 | ||
| Full | 45 (98) | 1 (2) | |
| Mixed | 13 (81) | 3 (19) |
| Chimerism . | No de novo autoimmunity at 6 mo or later . | De novo autoimmunity at 6 mo or later . | P . |
|---|---|---|---|
| At 6 mo | |||
| All chimerism (n = 82)* | .3938 | ||
| Full | 45 (96) | 2 (4) | |
| Mixed | 31 (89) | 4 (11) | |
| T-cell chimerism (n = 65) | .5995 | ||
| Full | 45 (94) | 3 (6) | |
| Mixed | 15 (88) | 2 (12) | |
| B-cell chimerism (n = 48) | .2865 | ||
| Full | 41 (95) | 2 (5) | |
| Mixed | 4 (80) | 1 (20) | |
| Myeloid chimerism (n = 62) | .0494 | ||
| Full | 45 (98) | 1 (2) | |
| Mixed | 13 (81) | 3 (19) |
Data are expressed as the number of recipients (percentage of total in chimerism subgroup).
All chimerism was defined as any chimerism lineage measured (T-cell, B-cell, myeloid, whole-blood, or peripheral blood mononuclear cell). If a patient had mixed chimerism (≤95%) in any lineage, it was coded as mixed. The 6-month analysis of autoimmune disease included only patients who were alive and did not have de novo autoimmune disease prior to 6 months after HCT.